Format

Send to

Choose Destination
Biomed Pharmacother. 2017 Sep;93:713-720. doi: 10.1016/j.biopha.2017.05.127. Epub 2017 Jul 9.

Astilbin decreases proliferation and improves differentiation in HaCaT keratinocytes.

Author information

1
Department of Dermato-venereology, the Second Hospital of Shandong University, Jinan, China.
2
Department of Dermato-venereology, the Second Hospital of Shandong University, Jinan, China. Electronic address: cmzhang1878@163.com.

Abstract

Psoriasis is a common chronic dermatosis characterized by keratinocyte hyperproliferation accompanied by inflammatory reactions. Pathological changes upset the balance between keratinocyte proliferation, differentiation, and death in psoriatic lesions, suggesting that molecules with topical anti-inflammatory, anti-proliferation and anti-angiogenesis abilities may be useful for its treatment. The flavonoid astilbin is the major active component extracted from the rhizome of Smilax glabra, which has been widely used in China to treat inflammatory and autoimmune diseases. Here, we investigate the potential of astilbin as a treatment for psoriasis. We reveal that astilbin inhibits the growth of HaCaT keratinocytes. Detailed study shows that astilbin leads to S phase arrest of the cell cycle by induction of p53 and p21 and activated-AMPK. Additionally, astilbin induced keratinocyte differentiation correlated with suppression of keratin 5 (KRT5) and KRT14 proteins (the markers of epidermal basal layer) and induction KRT1 and KRT10 proteins (occurring in the upper layers). Moreover, astilbin regulates the expression of VEGF in human HaCaT keratinocytes. These results suggest that astilbin may be a promising agent for psoriasis treatment.

KEYWORDS:

Astilbin; HaCaT; Keratinocyte differentiation; Psoriasis; VEGF

PMID:
28700975
DOI:
10.1016/j.biopha.2017.05.127
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center